bluebird bio Inc (NASDAQ:BLUE) has received an average recommendation of “Hold” from the twenty-five research firms that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, ten have given a hold recommendation, twelve have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $167.00.
BLUE has been the subject of several research reports. Wedbush reissued an “outperform” rating and set a $174.00 price objective (up from $135.00) on shares of bluebird bio in a report on Thursday, November 2nd. Maxim Group boosted their price objective on shares of bluebird bio from $170.00 to $200.00 and gave the company a “buy” rating in a report on Thursday, November 30th. Cantor Fitzgerald reissued a “sell” rating and set a $58.00 price objective (up from $39.00) on shares of bluebird bio in a report on Wednesday, November 1st. Barclays reissued an “overweight” rating and set a $209.00 price objective (up from $162.00) on shares of bluebird bio in a report on Wednesday, December 13th. Finally, Morgan Stanley raised shares of bluebird bio from an “underweight” rating to an “equal weight” rating in a report on Friday, November 3rd.
bluebird bio (NASDAQ BLUE) traded up $5.70 on Friday, hitting $197.50. 560,400 shares of the stock traded hands, compared to its average volume of 933,790. bluebird bio has a 1 year low of $73.95 and a 1 year high of $222.03. The stock has a market capitalization of $9,050.00, a PE ratio of -28.17 and a beta of 2.07.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. grew its position in bluebird bio by 6.4% during the fourth quarter. BlackRock Inc. now owns 3,831,371 shares of the biotechnology company’s stock valued at $682,366,000 after buying an additional 231,697 shares during the period. Orbimed Advisors LLC boosted its position in shares of bluebird bio by 20.5% in the third quarter. Orbimed Advisors LLC now owns 481,946 shares of the biotechnology company’s stock worth $66,195,000 after purchasing an additional 82,146 shares during the period. Bank of New York Mellon Corp boosted its position in shares of bluebird bio by 32.9% in the fourth quarter. Bank of New York Mellon Corp now owns 326,446 shares of the biotechnology company’s stock worth $58,141,000 after purchasing an additional 80,883 shares during the period. Schwab Charles Investment Management Inc. boosted its position in shares of bluebird bio by 11.0% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 296,073 shares of the biotechnology company’s stock worth $52,731,000 after purchasing an additional 29,380 shares during the period. Finally, Eagle Asset Management Inc. bought a new position in shares of bluebird bio in the third quarter worth approximately $29,539,000.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.